BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 23165618)

  • 1. Irreversible electroporation for the ablation of liver tumors: are we there yet?
    Charpentier KP
    Arch Surg; 2012 Nov; 147(11):1053-61. PubMed ID: 23165618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ablation of perivascular hepatic malignant tumors with irreversible electroporation.
    Kingham TP; Karkar AM; D'Angelica MI; Allen PJ; Dematteo RP; Getrajdman GI; Sofocleous CT; Solomon SB; Jarnagin WR; Fong Y
    J Am Coll Surg; 2012 Sep; 215(3):379-87. PubMed ID: 22704820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.
    Martin RC; Kwon D; Chalikonda S; Sellers M; Kotz E; Scoggins C; McMasters KM; Watkins K
    Ann Surg; 2015 Sep; 262(3):486-94; discussion 492-4. PubMed ID: 26258317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous Ablation of Hepatic Tumors Using Irreversible Electroporation: A Prospective Safety and Midterm Efficacy Study in 34 Patients.
    Niessen C; Beyer LP; Pregler B; Dollinger M; Trabold B; Schlitt HJ; Jung EM; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2016 Apr; 27(4):480-6. PubMed ID: 26922979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irreversible Electroporation of Malignant Hepatic Tumors--Alterations in Venous Structures at Subacute Follow-Up and Evolution at Mid-Term Follow-Up.
    Dollinger M; Müller-Wille R; Zeman F; Haimerl M; Niessen C; Beyer LP; Lang SA; Teufel A; Stroszczynski C; Wiggermann P
    PLoS One; 2015; 10(8):e0135773. PubMed ID: 26270651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irreversible Electroporation for Colorectal Liver Metastases.
    Scheffer HJ; Melenhorst MC; Echenique AM; Nielsen K; van Tilborg AA; van den Bos W; Vroomen LG; van den Tol PM; Meijerink MR
    Tech Vasc Interv Radiol; 2015 Sep; 18(3):159-69. PubMed ID: 26365546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is irreversible electroporation safe and effective in the treatment of hepatobiliary and pancreatic cancers?
    Wu LM; Zhang LL; Chen XH; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Apr; 18(2):117-124. PubMed ID: 30655073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irreversible Electroporation in the Treatment of Hepatocellular Carcinoma.
    Lencioni R; Crocetti L; Narayanan G
    Tech Vasc Interv Radiol; 2015 Sep; 18(3):135-9. PubMed ID: 26365542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma.
    Martin RC; McFarland K; Ellis S; Velanovich V
    J Am Coll Surg; 2012 Sep; 215(3):361-9. PubMed ID: 22726894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiofrequency ablation: the experts weigh in.
    Tanabe KK; Curley SA; Dodd GD; Siperstein AE; Goldberg SN
    Cancer; 2004 Feb; 100(3):641-50. PubMed ID: 14745883
    [No Abstract]   [Full Text] [Related]  

  • 11. Electrode activation sequencing employing conductivity changes in irreversible electroporation tissue ablation.
    Sahakian AV; Al-Angari HM; Adeyanju OO
    IEEE Trans Biomed Eng; 2012 Mar; 59(3):604-7. PubMed ID: 22194234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pain analysis in patients with hepatocellular carcinoma: irreversible electroporation versus radiofrequency ablation-initial observations.
    Narayanan G; Froud T; Lo K; Barbery KJ; Perez-Rojas E; Yrizarry J
    Cardiovasc Intervent Radiol; 2013 Feb; 36(1):176-82. PubMed ID: 22752100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midterm Safety and Efficacy of Irreversible Electroporation of Malignant Liver Tumors Located Close to Major Portal or Hepatic Veins.
    Distelmaier M; Barabasch A; Heil P; Kraemer NA; Isfort P; Keil S; Kuhl CK; Bruners P
    Radiology; 2017 Dec; 285(3):1023-1031. PubMed ID: 28799842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results.
    Frühling P; Nilsson A; Duraj F; Haglund U; Norén A
    Eur J Surg Oncol; 2017 Apr; 43(4):751-757. PubMed ID: 28109674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance of radiofrequency ablation by patients of hepatocellular carcinoma.
    Cheung TT; Ng KK; Poon RT; Fan ST
    J Hepatobiliary Pancreat Surg; 2009; 16(5):655-60. PubMed ID: 19370304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience.
    Dollinger M; Beyer LP; Haimerl M; Niessen C; Jung EM; Zeman F; Stroszczynski C; Wiggermann P
    Diagn Interv Radiol; 2015; 21(6):471-5. PubMed ID: 26359870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of thermal injury to liver, pancreas and kidney during irreversible electroporation in an in vivo experimental model.
    Dunki-Jacobs EM; Philips P; Martin RC
    Br J Surg; 2014 Aug; 101(9):1113-21. PubMed ID: 24961953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.
    Ueno S; Sakoda M; Kubo F; Hiwatashi K; Tateno T; Baba Y; Hasegawa S; Tsubouchi H;
    J Hepatobiliary Pancreat Surg; 2009; 16(3):359-66. PubMed ID: 19300896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irreversible electroporation of the liver and liver hilum in swine.
    Charpentier KP; Wolf F; Noble L; Winn B; Resnick M; Dupuy DE
    HPB (Oxford); 2011 Mar; 13(3):168-73. PubMed ID: 21309933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irreversible electroporation: a new ablation modality--clinical implications.
    Rubinsky B; Onik G; Mikus P
    Technol Cancer Res Treat; 2007 Feb; 6(1):37-48. PubMed ID: 17241099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.